Tiziana Life Sciences Ltd.

Contributing Author

Recent Articles by Tiziana Life Sciences Ltd.

Jan-20	Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab TLSA +8.23% TLSA -5.95% GlobeNewswire
Jan-16	Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares TLSA +15.86% GlobeNewswire
Jan-16	Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million TLSA +15.86% GlobeNewswire
Jan-09	Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco TLSA GlobeNewswire
Dec-29	Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA TLSA GlobeNewswire
Dec-19	Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman TLSA +5.56% GlobeNewswire
Dec-17	Tiziana Life Sciences to Ring the Closing Bell at Nasdaq TLSA -5.81% GlobeNewswire
Dec-17	Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial TLSA -5.81% GlobeNewswire
Dec-15	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer TLSA -10.67% GlobeNewswire
Dec-15	Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering TLSA -10.67% GlobeNewswire
Dec-12	Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial TLSA GlobeNewswire
Dec-02	Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company TLSA GlobeNewswire
Nov-25	Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program TLSA +5.20% GlobeNewswire
Nov-13	Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference TLSA -7.30% GlobeNewswire
Oct-29	Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy TLSA GlobeNewswire
Sep-30	Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia TLSA GlobeNewswire
Sep-25	Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody TLSA +5.08% GlobeNewswire
Sep-24	Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress TLSA +11.93% GlobeNewswire
Sep-15	Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury TLSA GlobeNewswire
Sep-09	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer TLSA +14.20% GlobeNewswire
Sep-09	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer TLSA +14.20% GlobeNewswire
Sep-05	Tiziana Life Sciences Announces Purchase of Shares by Chairman TLSA +5.06% GlobeNewswire
Aug-14	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy TLSA -6.10% GlobeNewswire
Aug-11	FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy TLSA +11.82% GlobeNewswire
Jul-21	Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient TLSA GlobeNewswire
Jun-13	Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center TLSA +9.15% GlobeNewswire
Jun-13	Tiziana Life Sciences to Present at the Bio International Convention TLSA +9.15% GlobeNewswire
May-23	Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease TLSA +15.33% GlobeNewswire
May-15	Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease TLSA GlobeNewswire
May-12	Tiziana Life Sciences Announces Purchase of Shares by Chairman TLSA GlobeNewswire
May-09	Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab TLSA GlobeNewswire
May-06	Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis TLSA +22.95% GlobeNewswire

Tiziana Life Sciences Ltd.

Recent Articles by Tiziana Life Sciences Ltd.

Upgrade your FINVIZ experience